NYSE:BHVN Biohaven (BHVN) Stock Forecast, Price & News $17.65 +0.41 (+2.38%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$17.17▼$18.1550-Day Range$16.93▼$25.5252-Week Range$5.54▼$26.64Volume849,717 shsAverage Volume969,315 shsMarket Capitalization$1.21 billionP/E RatioN/ADividend YieldN/APrice Target$25.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Biohaven MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside43.1% Upside$25.25 Price TargetShort InterestBearish9.03% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$2.90 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($4.99) to ($4.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.35 out of 5 starsMedical Sector242nd out of 964 stocksPharmaceutical Preparations Industry93rd out of 439 stocks 3.5 Analyst's Opinion Consensus RatingBiohaven has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.25, Biohaven has a forecasted upside of 43.1% from its current price of $17.65.Amount of Analyst CoverageBiohaven has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.03% of the float of Biohaven has been sold short.Short Interest Ratio / Days to CoverBiohaven has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Biohaven has recently decreased by 4.89%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldBiohaven does not currently pay a dividend.Dividend GrowthBiohaven does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BHVN. Previous Next 3.3 News and Social Media Coverage News SentimentBiohaven has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Biohaven this week, compared to 2 articles on an average week.Search Interest7 people have searched for BHVN on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat Follows7 people have added Biohaven to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biohaven insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,900,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders15.50% of the stock of Biohaven is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.60% of the stock of Biohaven is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biohaven are expected to grow in the coming year, from ($4.99) to ($4.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biohaven is -2.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biohaven is -2.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiohaven has a P/B Ratio of 2.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Biohaven (NYSE:BHVN) StockBiohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.Read More BHVN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BHVN Stock News HeadlinesSeptember 22, 2023 | finance.yahoo.comBiohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular AtrophySeptember 19, 2023 | americanbankingnews.comBiohaven Ltd. (NYSE:BHVN) Receives Consensus Rating of "Buy" from BrokeragesSeptember 27, 2023 | Legacy Research (Ad)ATTENTION: Digital Dollar Could Send this $0.25 Play SkyrocketingIn just a few days, the U.S. government could announce this mandatory recall on the U.S. dollar… And replace it with a new digital dollar. And that could send this $0.25 alternative investment skyrocketing.September 5, 2023 | markets.businessinsider.comBiohaven Reports Positive Data From EEG Biomarker Study Of BHV-7000September 5, 2023 | finance.yahoo.comBiohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal StudiesAugust 28, 2023 | seekingalpha.comBiohaven's Valuation Challenge: Weighing Potential Against SetbacksAugust 16, 2023 | msn.comJP Morgan Maintains Biohaven (BHVN) Overweight RecommendationAugust 15, 2023 | fool.comBiohaven (NYSE: BHVN)September 27, 2023 | Legacy Research (Ad)ATTENTION: Digital Dollar Could Send this $0.25 Play SkyrocketingIn just a few days, the U.S. government could announce this mandatory recall on the U.S. dollar… And replace it with a new digital dollar. And that could send this $0.25 alternative investment skyrocketing.August 9, 2023 | finance.yahoo.comIndependent Director of Biohaven Picks Up 1.8% More StockAugust 8, 2023 | benzinga.com$2M Bet On Biohaven? Check Out These 4 Stocks Insiders Are BuyingAugust 3, 2023 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVNJuly 31, 2023 | finance.yahoo.comBiohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular AtrophyJuly 31, 2023 | finance.yahoo.comBiohaven Reports Second Quarter 2023 Financial Results and Recent Business DevelopmentsJuly 28, 2023 | markets.businessinsider.comBiohaven Stock Is Plunging Today - Here's WhyJuly 28, 2023 | seekingalpha.comBiohaven falls as FDA rejects filing for movement disorder therapyJuly 28, 2023 | msn.comBiohaven (NYSE:BHVN) Tanks on FDA Snub for Troriluzole in SCAJuly 28, 2023 | finance.yahoo.comWhy Biohaven Stock Is Crashing TodayJuly 27, 2023 | finance.yahoo.comBiohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate UpdatesJuly 17, 2023 | msn.comCantor Fitzgerald Reiterates Biohaven (BHVN) Overweight RecommendationJuly 4, 2023 | finance.yahoo.comBHVN - Biohaven Ltd.June 15, 2023 | seekingalpha.comBiohaven: A Promising Investment In Innovative Neurological TherapiesJune 6, 2023 | seekingalpha.comBiohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A HeadacheJune 6, 2023 | msn.comBTIG Reiterates Biohaven (BHVN) Buy RecommendationJune 5, 2023 | markets.businessinsider.comBiohaven Ltd. (BHVN) Gets a Buy from BTIGJune 1, 2023 | seekingalpha.comBiohaven hits an all-time high after R&D DayJune 1, 2023 | finance.yahoo.comHow Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day RunSee More Headlines Receive BHVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter. Email Address BHVN Company Calendar Last Earnings7/31/2023Today9/27/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:BHVN Previous SymbolNASDAQ:BHVN CUSIPN/A CIK1689813 Webwww.biohavenpharma.com Phone203-404-0410FaxN/AEmployees928Year FoundedN/APrice Target and Rating Average Stock Price Forecast$25.25 High Stock Price Forecast$31.00 Low Stock Price Forecast$21.00 Forecasted Upside/Downside+43.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($7.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-570,280,000.00 Net MarginsN/A Pretax Margin-255.54% Return on Equity-114.99% Return on Assets-89.62% Debt Debt-to-Equity RatioN/A Current Ratio4.94 Quick Ratio4.94 Sales & Book Value Annual Sales$462.51 million Price / Sales2.61 Cash FlowN/A Price / Cash FlowN/A Book Value$7.90 per share Price / Book2.23Miscellaneous Outstanding Shares68,320,000Free Float57,728,000Market Cap$1.21 billion OptionableOptionable Beta1.12 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Vladimir Coric M.D. (Age 52)Chairman & CEO Comp: $1.85MMr. Matthew Buten (Age 62)Chief Financial Officer Comp: $939.45kDr. Bruce D. Car DACVP (Age 61)Ph.D., Chief Scientific Officer Comp: $646.89kMs. Deb YoungDirector of Regulatory Affairs & OperationsMr. George C. Clark (Age 39)VP & Chief Accounting Officer Ms. Jennifer PorcelliVP of Investor RelationsMr. Warren Volles J.D.Gen. Counsel & Chief Legal OfficerMr. Clifford Bechtold M.S.Chief Compliance OfficerMs. Kimberly Gentile (Age 57)Sr. VP of Clinical Operations Mr. John Tilton (Age 55)Chief Commercial Officer of Rare Diseases More ExecutivesKey CompetitorsOPKO HealthNASDAQ:OPKXencorNASDAQ:XNCRViking TherapeuticsNASDAQ:VKTXANI PharmaceuticalsNASDAQ:ANIP89bioNASDAQ:ETNBView All CompetitorsInsiders & InstitutionsJohn W ChildsBought 50,000 shares on 8/30/2023Total: $922,000.00 ($18.44/share)Perceptive Advisors LLCBought 320,820 shares on 8/24/2023Ownership: 0.470%California State Teachers Retirement SystemSold 6,998 shares on 8/21/2023Ownership: 0.103%Alliancebernstein L.P.Sold 500 shares on 8/15/2023Ownership: 0.102%Royal Bank of CanadaBought 3,187 shares on 8/15/2023Ownership: 0.018%View All Insider TransactionsView All Institutional Transactions BHVN Stock - Frequently Asked Questions Should I buy or sell Biohaven stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biohaven in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BHVN shares. View BHVN analyst ratings or view top-rated stocks. What is Biohaven's stock price forecast for 2023? 6 brokerages have issued 1-year target prices for Biohaven's shares. Their BHVN share price forecasts range from $21.00 to $31.00. On average, they expect the company's stock price to reach $25.25 in the next twelve months. This suggests a possible upside of 43.1% from the stock's current price. View analysts price targets for BHVN or view top-rated stocks among Wall Street analysts. How have BHVN shares performed in 2023? Biohaven's stock was trading at $13.88 at the beginning of the year. Since then, BHVN stock has increased by 27.2% and is now trading at $17.65. View the best growth stocks for 2023 here. Are investors shorting Biohaven? Biohaven saw a increase in short interest during the month of August. As of August 15th, there was short interest totaling 5,520,000 shares, an increase of 12.7% from the July 31st total of 4,900,000 shares. Based on an average trading volume of 1,130,000 shares, the days-to-cover ratio is currently 4.9 days. Currently, 9.5% of the shares of the company are sold short. View Biohaven's Short Interest. When is Biohaven's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our BHVN earnings forecast. How were Biohaven's earnings last quarter? Biohaven Ltd. (NYSE:BHVN) issued its quarterly earnings data on Monday, July, 31st. The company reported ($1.32) EPS for the quarter, missing analysts' consensus estimates of ($1.18) by $0.14. What ETFs hold Biohaven's stock? ETFs with the largest weight of Biohaven (NYSE:BHVN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Invesco Dorsey Wright Healthcare Momentum ETF (PTH). What other stocks do shareholders of Biohaven own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT). When did Biohaven IPO? (BHVN) raised $124 million in an IPO on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers. What is Biohaven's stock symbol? Biohaven trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN." Who are Biohaven's major shareholders? Biohaven's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.49%), Suvretta Capital Management LLC (5.66%), State Street Corp (4.20%), Holocene Advisors LP (3.02%), Geode Capital Management LLC (1.76%) and Point72 Asset Management L.P. (1.71%). Insiders that own company stock include Declan Doogan, Elyse Stock, George C Clark, Gregory Bailey, James Engelhart, John W Childs, Julia P Gregory, Kimberly Gentile, Matthew Buten, Vlad Coric and William A Jones Jr. View institutional ownership trends. How do I buy shares of Biohaven? Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Biohaven's stock price today? One share of BHVN stock can currently be purchased for approximately $17.65. How much money does Biohaven make? Biohaven (NYSE:BHVN) has a market capitalization of $1.21 billion and generates $462.51 million in revenue each year. The company earns $-570,280,000.00 in net income (profit) each year or ($7.42) on an earnings per share basis. How many employees does Biohaven have? The company employs 928 workers across the globe. How can I contact Biohaven? Biohaven's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The official website for the company is www.biohavenpharma.com. The company can be reached via phone at 203-404-0410 or via email at jennifer.porcelli@biohavenpharma.com. This page (NYSE:BHVN) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biohaven Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.